Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab

Código QR

Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab

Guardado en:

Detalles Bibliográficos
Autores principales:	Alexander N Shoushtari, Katherine S Panageas, Jedd D Wolchok, Paul B Chapman, Margaret Callahan, Allison Betof Warner, Vetri Sudar Jayaprakasam
Formato:	article
Lenguaje:	EN
Publicado:	BMJ Publishing Group 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/c887a53451914cb28a74ca903b635a10
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ipilimumab and Nivolumab induced ventricular tachycardia in a patient with metastatic renal cell carcinoma
por: Pramod Savarapu, et al.
Publicado: (2021)

Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab
por: Tian Zhang, et al.
Publicado: (2021)

A Case of Vogt-Koyanagi-Harada Disease-Like Uveitis Induced by Nivolumab and Ipilimumab Combination Therapy
por: Keisuke Minami, et al.
Publicado: (2021)

Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma
por: Matthew D. Tucker, et al.
Publicado: (2021)

Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES)
por: Shahneen Sandhu, et al.
Publicado: (2021)

Use of ipilimumab in the treatment of melanoma
por: Acharya UH, et al.
Publicado: (2013)

Trough levels of ipilimumab in serum as a potential biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab
por: William L Redmond, et al.
Publicado: (2021)

Comparison of Efficacy in Patients with Metastatic Melanoma Treated with Ipilimumab and Nivolumab Who Did or Did Not Discontinue Treatment Due to Immune-Related Adverse Events: A Real-World Data Study
por: Morten Fink, et al.
Publicado: (2021)

Utility of Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Systemic Immune Inflammation Index as Prognostic, Predictive Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab and Ipilimumab
por: Koji Iinuma, et al.
Publicado: (2021)

Cost-Effectiveness of Ipilimumab Plus Anti-PD-1 Therapy Versus Ipilimumab Alone in Patients With Metastatic Melanoma Resistant to Anti-PD-(L)1 Monotherapy
por: Ye Peng, et al.
Publicado: (2021)

IgA Nephropathy Secondary to Ipilimumab Use
por: Sean C. Dougherty, et al.
Publicado: (2021)

Phase II Study of Nivolumab Plus Ipilimumab with Platinum-Based Chemotherapy for Treatment-Naïve Advanced Non-Small Cell Lung Cancer with Untreated Brain Metastases: NIke Trial (LOGiK2004)
por: Tsuchiya-Kawano Y, et al.
Publicado: (2021)

Complete regression of metastatic malignant melanoma endoscopically after nivolumab administration
por: Dae Gon Ryu, et al.
Publicado: (2021)

Autoimmune hemolytic anemia during long‐term administration of nivolumab for metastatic melanoma
por: Koji Nakajima, et al.
Publicado: (2021)

Maculopapular erythema caused by previously used chemotherapy drugs after nivolumab treatment for malignant mesothelioma
por: Junko Kanai, et al.
Publicado: (2021)

Nivolumab-Induced Exocrine Pancreatic Insufficiency
por: Boudewijn Sweep, et al.
Publicado: (2021)

MET Amplification and Efficacy of Nivolumab in Patients With NSCLC
por: Katsuhiro Yoshimura, MD, PhD, et al.
Publicado: (2021)

Use of nivolumab for colon cancer with Lynch syndrome
por: G. A. Khakimov, et al.
Publicado: (2020)

Nivolumab-associated DRESS in a genetic susceptible individual
por: Qian Li, et al.
Publicado: (2021)

IL-10 Signaling Elicited by Nivolumab-Induced Activation of the MAP Kinase Pathway Does Not Fully Contribute to Nivolumab-Modulated Heterogeneous T Cell Responses
por: Taylor A. Harper, et al.
Publicado: (2021)

An Open–Label, Randomized, Multi–Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin–2) and Ipilimumab (Yervoy) in Patients with Metastatic Melanoma
por: Merve Hasanov, et al.
Publicado: (2021)

An unexpected N-terminal loop in PD-1 dominates binding by nivolumab
por: Shuguang Tan, et al.
Publicado: (2017)

Nivolumab-induced new-onset seronegative rheumatoid arthritis in a patient with advanced metastatic melanoma: A case report and literature review
por: Ammar Haikal, et al.
Publicado: (2018)

Novel Prognostic Score for recurrent or metastatic head and neck cancer patients treated with Nivolumab
por: Kiyoshi Minohara, et al.
Publicado: (2021)

Combination of gene set signatures correlates with response to nivolumab in platinum-resistant ovarian cancer
por: Ryusuke Murakami, et al.
Publicado: (2021)

New targeted treatments for non-small-cell lung cancer – role of nivolumab
por: Zago G, et al.
Publicado: (2016)

THE EFFECT OF NIVOLUMAB IN PEDIATRIC MALIGNANT TUMORS: A SINGLE CENTER EXPERIENCE WITH EIGHT PATIENTS
por: Veysel GOK, et al.
Publicado: (2021)

Tumor Lysis Syndrome following a Single Dose of Nivolumab for Relapsed Small-Cell Lung Cancer
por: Sarah Maryon Hayes, et al.
Publicado: (2021)

Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study
por: Romualdo Barroso-Sousa, et al.
Publicado: (2021)

Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity study
por: David Goldstein, et al.
Publicado: (2021)

Correlation between immune-related adverse events and therapeutic effects of nivolumab in patients with malignant pleural mesothelioma
por: Hiroto Yoneda, et al.
Publicado: (2021)

Molecular phenotypes of circulating tumor cells and efficacy of nivolumab treatment in patients with head and neck squamous cell carcinoma
por: Hiroe Tada, et al.
Publicado: (2020)

Impact of C-reactive protein flare-response on oncological outcomes in patients with metastatic renal cell carcinoma treated with nivolumab
por: Toshiki Kijima, et al.
Publicado: (2021)

JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma
por: Nobukazu Fujimoto, et al.
Publicado: (2021)

Effect of antibiotic use on the efficacy of nivolumab in the treatment of advanced/metastatic non-small cell lung cancer: A meta-analysis
por: Huo Geng-wei, et al.
Publicado: (2021)

Correction: Impact of C-reactive protein flare-response on oncological outcomes in patients with metastatic renal cell carcinoma treated with nivolumab
Publicado: (2021)

Do endocrine adverse events predict longer progression-free survival among patients with non-small-cell lung cancer receiving nivolumab?
por: Izabela Chmielewska, et al.
Publicado: (2021)

Body mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumab
por: Rosaria De Filippi, et al.
Publicado: (2021)

Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis
por: Krista Dubin, et al.
Publicado: (2016)

Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated With Expansion and Maturation of NK Cells
por: Fabio Guolo, et al.
Publicado: (2021)